

Title

Tau PET visual reads find sources of tau not explained by typical Alzheimer disease pathophysiology

Authors

Charles D. Chen^{1*}, Maria Rosana Ponisio^{1*}, Jordan A. Lang¹, Shaney Flores¹, Suzanne E. Schindler², Anne M. Fagan², John C. Morris², Tammie L.S. Benzinger¹

¹Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO 63110, USA

²Department of Neurology, Washington University in St. Louis, St. Louis, MO 63110, USA

Corresponding author

Tammie L.S. Benzinger

Washington University School of Medicine

660 South Euclid

Campus Box 8225

St. Louis, MO 63110, USA

Telephone: (314) 362-1558

Fax: (314) 362-5297

benzinger@wustl.edu

Abstract

¹⁸F-flortaucipir-PET received FDA approval to visualize tauopathy in the brains of adult patients with cognitive impairment being evaluated for Alzheimer disease (AD). However, manufacturer's guidelines for the visual interpretation of ¹⁸F-flortaucipir-PET differs greatly from how ¹⁸F-flortaucipir-PET has been measured in research settings using standardized uptake value ratios (SUVRs). How visual interpretation relates to ¹⁸F-flortaucipir-PET SUVR, CSF biomarkers, or longitudinal clinical assessment is not well understood. Here we compare these various diagnostic methods in participants enrolled in studies of aging and memory (n=189, of whom 23 were cognitively impaired). Visual interpretation had high agreement with SUVR (98.4%); discordant participants had hemorrhagic infarcts or atypical AD tauopathies. Visual interpretation had moderate agreement with CSF p-tau181 (86.1%). Two participants demonstrated ¹⁸F-flortaucipir uptake from meningiomas. Visual interpretation could not predict follow-up clinical assessment in 9.52% of cases. We conclude that close association between AD tauopathy and clinical onset in group-level studies does not always hold at the individual level, with discrepancies arising from atypical AD, vascular dementia, or frontotemporal dementia. A better understanding of relationships across imaging, CSF biomarkers, and clinical assessment is needed to provide appropriate diagnoses for these individuals.

Key words: Alzheimer disease/cerebrospinal fluid/clinical diagnosis/¹⁸F-flortaucipir PET/visual interpretation

Introduction

The pathological hallmarks of Alzheimer disease (AD) are amyloid- β (A β) plaques and misfolded hyperphosphorylated tau neurofibrillary tangles (NFTs) [1,2]. *In vivo* evaluation of aggregated tau or associated pathophysiology in AD was first performed using immunoassays for cerebrospinal fluid (CSF) tau phosphorylated at position 181 (p-tau) [3]. Later, tau PET radiotracers were developed [4–6], along with methods for tau PET standardized uptake value ratio (SUVR) analyses [7,8]. The first generation of tau PET radiotracers includes the arylquinoline derivatives ^{18}F -THK5317 and ^{18}F -THK5351, the pyridoindole derivative ^{18}F -flortaucipir, and the phenyl/pyridinyl-butadienyl-benzothiazole/benzothiazolium derivative ^{11}C -PBB3. Among these, ^{18}F -flortaucipir (TauvidTM, Avid Radiopharmaceuticals) became the first to be approved by the United States Food and Drug Administration to estimate the density and distribution of aggregated tau NFTs in adult patients with cognitive impairment being evaluated for AD. Following the manufacturer's guidelines for performing a visual interpretation of ^{18}F -flortaucipir PET imaging involves identifying the presence or absence of confluent radiotracer uptake greater than 1.65 times the cerebellar uptake in either the posterolateral temporal, occipital, or parietal/precuneus regions. This method differs greatly from most research procedures for automated quantification of tau PET imaging data, such as taking the volume-weighted mean standardized uptake value ratio (SUVR) in a temporal meta-region of interest (ROI) and comparing that to a cohort-defined threshold [7,8]. These methodological differences may lead to disagreements between visual interpretation and SUVR quantification. In particular, the temporal meta-ROI used in SUVR quantification does not contain any of the occipital or parietal/precuneus structures used in visual interpretation, and includes several medial temporal lobe structures ignored in visual interpretation. Additionally, in the clinic ^{18}F -flortaucipir PET imaging is only indicated for use in adult patients with cognitive impairment who are being evaluated for AD, whereas in a research setting ^{18}F -flortaucipir PET imaging is performed regardless of cognitive status, calling into question whether ^{18}F -flortaucipir PET imaging is a reliable measure of tauopathy

during preclinical stages of AD. Tau pathophysiology can also be evaluated by measuring phosphorylated tau concentrations in the CSF, and several studies have provided additional evidence that tau PET is more strongly coupled to cognitive decline, whereas CSF p-tau181 is more tightly linked to preclinical AD [9–12]. Understanding where these three methods – tau PET visual interpretation, tau PET SUVR quantification, and CSF p-tau181 concentration – agree and differ may improve how we define AD tauopathy and AD clinical diagnoses.

Materials and Methods

Study participants

Participants selected for this study were enrolled in longitudinal observational studies of aging and memory at the Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight ADRC, n=189, of whom 23 were cognitively impaired, Table 1). All participants met the inclusion criteria of having a tau PET usable for visual reads, and an A β PET, MRI, and clinical and cognitive evaluation, all within 18 months; the majority of participants (n=144) also underwent lumbar puncture within 18 months of their tau PET scan. The study was approved by the institutional review board, and all participants or their designees signed an informed consent form.

Clinical and cognitive assessment

Participants were assessed clinically and cognitively using the neuropsychological test battery from the Uniform Data Set (UDS) [13], which includes the Clinical Dementia Rating (CDR[®]) [14] and the Mini Mental State Examination (MMSE) [15]. The CDR assesses three domains of cognition (memory, orientation, judgment and problem solving) and three domains of function (community affairs, home and hobbies, personal care); scores from the six domains can either be summed to yield the CDR Sum of Boxes score, or passed to a lookup table to yield the CDR Global score.

Tau PET acquisition

Participants were scanned on a Siemens Biograph 40 TruePoint (Siemens Healthineers). Participants received a single intravenous bolus injection (341 ± 29.8 MBq) of ^{18}F -flortaucipir (Tauvid™, Avid Radiopharmaceuticals). Emission data were collected 80-100 minutes post injection. List-mode data were reconstructed using ordered subset expectation maximization with three iterations and 21 subsets. A low-dose CT scan preceded PET acquisition for attenuation correction.

Tau PET SUVR

Reconstructed PET images were processed using the PET Unified Pipeline (<https://github.com/ysu001/PUP>) and coregistered to corresponding MR images [16,17]. After segmenting MR images into regions of interest (ROIs) using FreeSurfer version 5.3 [18], regional SUVRs were defined from the reconstructed PET images using a cerebellar gray reference region. The temporal meta-ROI SUVR was defined as the volume-weighted mean SUVR of the amygdala, entorhinal, fusiform, parahippocampal, inferior temporal, and middle temporal ROIs [7,8].

Tau PET visual interpretation

Two radiologists with training in nuclear medicine (J.A.L. and M.R.P.) followed the manufacturer's guidelines for ^{18}F -flortaucipir PET visual interpretation of participant scans using MIM Encore (MIM Software). Reconstructed PET images were coregistered with corresponding MR images. A ROI was drawn around the whole cerebellum in the axial plane that maximizes its cross-sectional area. A color scale with a rapid transition at 1.65 times the mean cerebellar counts was defined. The temporal lobe was divided into the anterolateral, anterior mesial, posterolateral, and posterior mesial temporal quadrants by placing the horizontal crosshair posterior to the brainstem nuclei, and the vertical

crosshair at the widest portion of the temporal pole. An image was considered positive if it showed confluent activity above the rapid transition/cutoff in the cortical gray matter of the posterolateral temporal, occipital, or parietal/precuneus regions. An image was considered negative if it showed no activity above the cutoff in the cortical gray matter of the posterolateral temporal, occipital, or parietal/precuneus regions, or if it showed activity above the cutoff in the cortical gray matter restricted to the medial temporal, anterolateral temporal and frontal regions. Off-target binding, which may be seen in the choroid plexus, striatum, and brainstem nuclei, and small foci of nonconfluent activity, which may be seen throughout the cortical gray matter, were not used when determining tau positivity. Radiologists were blinded to all other information about each participant. In addition to following the manufacturer's guidelines for ^{18}F -flortaucipir PET visual interpretation, in this study, radiologists also reported whether radiotracer activity was symmetric across left and right hemispheres and whether there was off-target binding in the choroid plexus, striatum, brainstem nuclei, or bone/meninges. Notable findings (such as incidental meningiomas) were also reported.

A β PET

Participants were scanned on either a Siemens Biograph 40 TruePoint, Biograph mMR, or Biograph Vision 600 (Siemens Healthineers). Participants received either a single intravenous bolus injection (539 ± 159 MBq) of ^{11}C -Pittsburgh compound B (PiB) or (369 ± 22.4 MBq) of ^{18}F -florbetapir (AmyvidTM, Avid Radiopharmaceuticals). Emission data were either collected 30-60 minutes post injection (^{11}C -PiB) or 50-70 minutes post injection (^{18}F -florbetapir). Reconstructed PET images were formed and pre-processed in the same manner as tau PET. An A β PET SUVR was defined for each radiotracer [16,17] and standardized to the Centiloid scale [19,20].

MR acquisition

Participants were scanned on either a Siemens Biograph mMR or Magnetom Vida (Siemens Healthineers). Across all scanners, T1-weighted head MR images were acquired using a magnetization prepared rapid gradient echo (MPRAGE) generalized autocalibrating partial parallel acquisition (GRAPPA) sequence using a repetition time=2300 ms, echo time=2.95 ms, flip angle=9°, at 1.1x1.1x1.2 mm³ voxel resolution.

CSF

CSF was collected under standardized operating procedures. Participants underwent lumbar puncture in the morning following overnight fasting and 20-30 ml of CSF was collected in a 50 ml polypropylene tube via gravity drip using an atraumatic Sprotte 22-gauge spinal needle. CSF samples were kept on ice and centrifuged at low speed within two hours of collection, then transferred to another 50 ml tube to remove cells. CSF was aliquoted at 500 µl into polypropylene tubes and stored at -80°C. Concentrations of CSF p-tau181, Aβ42, and Aβ40 were measured by chemiluminescent enzyme immunoassay using a fully automated platform (LUMIPULSE G1200, Fujirebio) according to the manufacturer's specifications.

Statistical analyses

Cutoffs for binarizing tau PET, Aβ PET, CSF p-tau181, and CSF Aβ42/Aβ40 values were determined by fitting a two-component univariate Manly mixture model [21] in R software [22] to all relevant baseline PET SUVR or CSF measurements available in the Knight ADRC Data Freeze 17 and finding the decision boundary. Manly mixture modeling was used to account for possible severe skewness in the data that would be difficult to model using Gaussian mixture modeling, and to account for skewness that can vary from component to component, which would be impossible to model using log or Box-Cox transformations [21]. Cohen's kappa (κ) was used to measure inter-rater reliability between the two

radiologists' tau PET visual interpretations, as well as between tau PET visual interpretation and tau PET SUVR quantification, and between tau PET visual interpretation and CSF p-tau181 concentration.

Results

Overall, participants were on average (\pm standard deviation) 69.8 \pm 8.51 years old, most were cognitively normal with a global Clinical Dementia Rating (CDR[®]) [14] of 0 (n=166/189, 87.8%) and most did not carry the *APOE* ϵ 4 allele (n=120/188, 63.8%). (Table 1). Cognitively normal participants had a mean tau PET temporal meta-ROI SUVR of 1.15 \pm 0.106 and a mean Centiloid of 19.9 \pm 34.4. Cognitively impaired participants (n=23/189, 12.2%) had a clinical diagnosis of either uncertain dementia (n=9), a CDR=0.5 in memory only (n=1), or AD dementia (n=13). They also had a mean tau PET temporal meta-ROI SUVR of 1.44 \pm 0.364 and a mean Centiloid of 74.3 \pm 45.6.

TABLE 1 Participant characteristics

		Cognitively normal	Cognitively impaired	Total
Number		166	23	189
Mean age in years (SD)		68.9 \pm 8.34	75.7 \pm 7.36	69.8 \pm 8.51
Female (%)		93 (56.0)	12 (52.2)	105 (55.6)
Race	White	147	23	170
	Black or African American	18	0	18
	Asian	1	0	1
Mean MMSE (SD)		29.2 (1.12)	26.0 (3.66)	28.8 (1.94)
CDR[®]	0	166	0	166
	0.5	0	16	16
	1	0	6	6
	2	0	1	1
Clinical diagnosis	Cognitively normal	166	0	166
	Uncertain dementia	0	9	9
	0.5 in memory only	0	1	1
	AD dementia	0	13	13
<i>APOE</i> genotype	2/2	1	0	1
	2/3	27	1	28
	2/4	6	1	7
	3/3	83	8	91
	3/4	42	11	53
	4/4	6	2	8
	Unknown	1	0	1
Tau PET temporal meta-ROI SUVR	Mean\pmSD	1.15 \pm 0.106 [0.924,	1.44 \pm 0.364 [1.024,	1.18 \pm 0.185 [0.924,
	[min, max]	1.882]	2.43]	2.43]
	Positive (%)	4 (2.41)	13 (56.5)	17 (8.99)
Tau PET visual	Positive (%)	6 (3.61)	14 (60.9)	20 (10.6)

interpretation

A β PET (Centiloid)	Mean \pm SD	19.9 \pm 34.4	74.3 \pm 45.6	26.5 \pm 40.0
Positive (%)		45 (27.1)	19 (82.6)	64 (33.9)

Abbreviations: CDR[®]=Clinical Dementia Rating[®], MMSE=Mini-Mental State Exam, SD=standard deviation.

To binarize A β and tau biomarker data, Manly mixture modeling was used to determine the following cutoffs: tau PET temporal meta-ROI SUVR cutoff=1.32, A β PET (Centiloid) cutoff=21.6, CSF p-tau181 cutoff=58.1 pg/ml, and CSF A β 42/A β 40 cutoff=0.0737.

Of the 189 ¹⁸F-flortaucipir PET images, 20 (10.6%) were read as positive by both radiologists. Both radiologists also read 169 images as negative and thus agreed on the overall visual interpretation of each image in the current study (n=189/189, 100%, κ =1). Agreement between visual interpretation and SUVR quantification was high (n=186/189, 98.4%, κ =0.910) (Figure 1).




FIGURE 1. Comparison of tau PET visual interpretation with tau PET SUVR. Each PET study was assessed by visual interpretation using the manufacturer's guidelines to determine positivity (x-axis) and by temporal meta-ROI SUVR analysis using a cutoff of SUVR=1.32 to determine positivity (y-axis). The color indicates the A β PET status for each case (positive A β PET, red; negative A β PET, blue; cutoff=21.6 Centiloids).

The three participants who had discordant results between visual interpretation and SUVR quantification all had tau-positive visual interpretations and tau-negative SUVRs. One participant (Figure 2a) demonstrated elevated ^{18}F -flortaucipir uptake in the right precuneus and was A β PET, CSF A β 42/A β 40, and CSF p-tau181 negative (Table 2). Additional MR imaging revealed a hypointensity on T2*-weighted MRI that colocalized with the elevated right precuneus radiotracer uptake on ^{18}F -flortaucipir PET (Figure 2b). The other two participants (Figures 2c and 2d) demonstrated lateralized occipital uptake, with greater uptake in either the left (Figure 2c) or right (Figure 2d), and were A β PET, CSF A β 42/A β 40, and CSF p-tau181 positive (Table 2). The participant with right occipital uptake also had posterolateral temporal and parietal/precuneus uptake.




FIGURE 2. Three cases with tau-positive visual interpretations, but tau-negative SUVRs. (A) Tau PET coregistered with MRI of a man in his 80s with elevated right precuneus uptake. (B) Corresponding T2*-weighted MRI showing a hypointensity that colocalizes with the elevated right precuneus uptake from (A). (C) Tau PET coregistered with MRI of a woman in her 70s with elevated occipital lobe uptake, left greater than right. (D) Tau PET coregistered with MRI of a woman in her 70s with elevated posterolateral temporal, occipital, and parietal/precuneus lobe uptake, right greater than left.

TABLE 2 AD biomarker status for cases with positive tau PET visual interpretation but negative tau PET SUVR analysis

	Age	Sex	APOE	CDR [®]	A β PET (Centiloid)	Tau PET (SUVR)	CSF A β 42/A β 40	CSF p-tau181 (pg/ml)
Parietal/precuneus hemorrhagic infarct	80s	Male	3/4	0	3.87	1.19	0.0975	21.6
Left occipital	70s	Female	3/4	0	17.0→ 50.0*	1.23	0.0523	69.2
Right occipital	70s	Female	3/3	0.5	72.1	1.31	0.0493	63.5

Numbers in bold denote positive biomarker status.

*This participant had a Centiloid=17.0 (below cutoff) approximately one year before their tau PET visit, and a Centiloid=50.0 (above cutoff) approximately two years after their tau PET visit.

In terms of incidental findings, frontal meningiomas were identified in two participants. One participant had a meningioma in their left posterior frontal lobe (Figure 3a and 3b); the other participant had it in their left frontal lobe (Figure 3c and 3d). Both meningiomas had elevated levels of radiotracer uptake. The first participant also had elevated right posterolateral temporal uptake and tau-positive visual interpretation and SUVR and was A β PET positive (Table 3). The other participant had tau-negative visual interpretation and SUVR and was A β PET negative.




FIGURE 3: Two cases of incidental meningioma with tau PET uptake. (A) Tau PET coregistered with MRI of a woman in her 70s with a left frontal posterior meningioma with tau radiotracer uptake. (B) Corresponding stand-alone tau PET image. (C) Corresponding stand-alone MRI image. (D) Tau PET coregistered with MRI of a man in his 70s with a left frontal meningioma with tau radiotracer uptake. (E) Corresponding stand-alone tau PET image. (F) Corresponding stand-alone MRI image.

TABLE 3 AD biomarker status for cases with incidental meningioma

	Age	Sex	APOE	CDR [®]	A β PET (Centiloid)	Tau PET (SUVR)	CSF A β 42/A β 40	CSF p- tau181 (pg/ml)
Left posterior frontal meningioma	70s	Female	2/4	0	177	1.64	0.0481*	49.9*
Left frontal meningioma	70s	Male	2/3	0	8.94	1.16	0.0848*	30.3*

Numbers in bold denote positive biomarker status.

*CSF lumbar punctures were performed approximately 10 years prior to tau PET

Agreement between visual interpretation and CSF p-tau181 was moderate (n=124/144, 86.1%, $\kappa=0.526$, Table 4). Two participants had tau-positive visual interpretations but were CSF p-tau181 negative (Figure 4a and 4b). One participant was previously identified as having a tau-positive visual interpretation but tau-negative SUVR (the same case as in Figure 2a and 2b). The other participant demonstrated posterolateral temporal uptake in both hemispheres and was A β PET and CSF A β 42/A β 40 positive. In

addition, 18 participants had tau-negative visual interpretations but were CSF p-tau181 positive (Figure 4a and 4b). These cases were mostly A β PET positive (n=14/18, 77.8%) and/or CSF A β 42/A β 40 positive (n=17/18, 94.4%).




FIGURE 4: Comparison of tau PET visual interpretation with CSF p-tau181 concentration. (A and B) Each participant is plotted by visual interpretation (x-axis) and CSF p-tau181 concentration (y-axis); participants with p-tau181 \geq 58.1 pg/ml were considered positive. In (A), the color indicates the A β PET status for each participant (positive A β PET, red; negative A β PET, blue; cutoff=21.6 Centiloid). In (B), the color indicates the CSF A β 42/A β 40 status for each participant (positive CSF A β 42/A β 40, red; negative CSF A β 42/A β 40, blue; cutoff=0.0737)

TABLE 4 Participant characteristics for those who underwent lumbar puncture

	Cognitively normal	Cognitively impaired	Total
Number	126	18	144
Mean age in years (SD)	68.6 \pm 8.32	76.1 \pm 7.84	69.5 \pm 8.60
Female (%)	70 (48.6)	10 (55.6)	80 (55.6)
Race			
White	114	18	132
Black or African American	11	0	11
Asian	1	0	1
Mean MMSE (SD)	29.3 (1.07)	25.7 (3.90)	28.8 (2.06)
CDR[®]			
0	126	0	126
0.5	0	12	12
1	0	5	5
2	0	1	1
Clinical diagnosis			
Cognitively normal	126	0	126
Uncertain dementia	0	6	6

APOE genotype	AD dementia	0	12	12
	2/2	1	0	1
	2/3	22	1	23
	2/4	3	1	4
	3/3	62	7	69
	3/4	31	7	38
	4/4	6	2	8
	Unknown	1	0	1
Tau PET temporal meta-ROI SUVR	Mean±SD [min, max]	1.15±0.108 [0.924, 1.882]	1.47±0.367 [1.042, 2.43]	1.19±0.194 [0.924, 2.43]
	Positive (%)	3 (2.38)	11 (61.1)	14 (9.72)
Tau PET visual interpretation	Positive (%)	5 (3.97)	12 (66.7)	17 (11.8)
	Aβ PET (Centiloid)	Mean±SD	19.0±32.2	80.3±46.7
CSF p-tau181	Positive (%)	34 (27.0)	16 (88.9)	50 (34.7)
	Mean±SD	42.6±30.4	88.7±42.6	48.4±35.5
CSF Aβ42/Aβ40	Positive (%)	19 (15.1)	14 (77.8)	33 (22.9)
	Mean±SD	0.0777±0.0217	0.0502±0.0196	0.0743±0.0233
	Positive (%)	41 (32.5)	16 (88.9)	57 (39.6)

Six participants were assessed at baseline to be cognitively normal but tau-positive on visual interpretation (Table 5). One participant (Case 1) was previously mentioned to have PET radiotracer uptake colocalized to a parietal/precuneus hypointensity on T2*-weighted MRI and no other positive AD biomarkers (Figure 2 and Table 2). The remaining five participants were all Aβ PET positive. No participant reliably converted from cognitively normal to AD dementia. One participant (Case 2) did convert to AD dementia at their three-year follow up, but was reassessed to have a clinical diagnosis of uncertain dementia, more specifically, possible non-AD dementia of vascular origin at their five-year follow up. Another participant (Case 4) converted to AD dementia at their two-year follow up, but was reassessed to have frontotemporal dementia (FTD) at their four-year follow up.

Four participants were assessed at baseline to be cognitively normal and tau-negative on visual interpretation, but would convert to AD dementia at follow up (Table 5). Two participants (Case 7 and Case 10) converted to AD dementia at their one-year follow ups, but were reassessed as cognitively normal at their two-year follow ups. The remaining two participants (Case 8 and Case 9) converted to AD dementia at their second- and fourth-year follow ups, respectively, but only Case 2 demonstrated Aβ PET positivity at baseline.

TABLE 5 Cognitively normal participant follow up

	Age	Sex	APOE	Baseline tau PET temporal meta-ROI	Baseline tau PET visual interpretation	Asymmetry	Baseline Aβ PET (Centiloid)	Yearly follow-up clinical diagnosis				
								1	2	3	4	5
Baseline cognitively normal and tau PET visual interpretation positive												
1*	80s	Male	3/4	1.19	Positive	Right	3.87	CN	CN	CN	CN	CN
2	70s	Male	2/3	1.35	Positive	Left	86.6		CN	AD	AD	UD
3**	70s	Female	3/4	1.23	Positive	Left	17.0→ 50.0	CN	CN	CN	CN	CN
4	80s	Male	3/3	1.88	Positive	Left	37.6	UD	AD	AD	FTD	
5	80s	Male	3/4	1.54	Positive		57.3	CN				
6***	70s	Female	2/4	1.64	Positive	Right	177	CN	CN	CN		
Baseline cognitively normal (and tau PET visual interpretation negative), but converts at follow up												
7	70s	Female	3/4	1.22	Negative		-2.35	AD	CN	CN		
8	80s	Female	3/4	1.21	Negative		120	CN	AD	AD		
9	50s	Male	3/3	0.93	Negative		3.38			UD	AD	
10****	70s	Male	2/3	1.16	Negative		8.94	AD	CN	CN		

Numbers in bold denote positive biomarker status.

Abbreviations: AD=Alzheimer disease (dementia), CN=cognitively normal, FTD=frontotemporal dementia, UD=uncertain dementia. *Same case as the “Parietal/precuneus hemorrhagic infarct” case in Table 2. **Same case as the “Left occipital” case in Table 2. ***Same case as the “Left posterior frontal meningioma” case in Table 3. ****Same case as the “Left frontal meningioma” case in Table 3.

Twenty-three participants were assessed at baseline to have cognitive impairment (Table 6). Nine of these participants received a clinical assessment of uncertain dementia and two of the nine had a baseline tau-positive visual assessment. Both cases (Case 2 and Case 4) converted to AD dementia by their first- and second-year follow ups, respectively and were both Aβ PET positive. Nonetheless, three cases with a tau-negative visual interpretation at baseline (Case 5, Case 7, and Case 8) converted to AD dementia at their two-, two-, and three-year follow ups, respectively, although Case 5 was reassessed to be cognitively normal at their five-year follow up.

Thirteen of the 23 participants with baseline cognitive impairment received a clinical assessment of AD dementia. All 13 participants were Aβ PET positive (Table 6). Twelve of these participants had tau-positive visual interpretation; the remaining participant (Case 18) was tau PET negative, but at their one-year follow up had their clinical assessment changed to frontotemporal dementia (FTD). Additionally, Case 21 was tau PET positive, but was reassessed to be cognitively normal at their one- and two-year follow ups.

TABLE 6 Cognitively impaired participant follow up

	Age	Sex	APOE	Baseline tau PET temporal meta-ROI	Baseline tau PET visual interpretation	Asymmetry	Baseline A β PET (Centiloid)	Yearly follow-up clinical diagnosis				
								1	2	3	4	5
Baseline uncertain dementia												
1	60s	Male	3/4	1.11	Negative		51.0		UD	UD	CN	UD
2	70s	Female	3/4	1.86	Positive		82.7	AD	AD	AD		
3	60s	Female	3/3	1.14	Negative	Right	37.6	CN		CN	CN	CN
4*	70s	Female	3/3	1.31	Negative	Right	72.1	UD	AD	AD	AD	
5	70s	Male	3/4	1.10	Negative	Right	77.9	CN	UD	AD	UD	CN
6	70s	Female	2/3	1.16	Negative		-25.7	UD				
7	80s	Male	2/4	1.04	Negative		9.49	CN	AD			
8	70s	Female	4/4	1.29	Negative		80.1		UD	AD	AD	
9	70s	Male	3/4	1.02	Negative	Right	19.2	CN	CN	CN	CN	
Baseline 0.5 in memory only												
10	80s	Male	3/3	1.07	Negative		12.2	CN	CN			
Baseline AD dementia												
11	70s	Female	3/4	1.57	Positive		54.7	AD	AD			
12	60s	Male	3/3	2.43	Positive		85.7					
13	70s	Female	3/4	2.08	Positive		60.1	AD	AD	AD	AD	
14	80s	Male	3/3	1.46	Positive		121	AD	AD			
15	80s	Male	3/4	1.35	Positive		87.5	AD	AD	AD	AD	
16	70s	Female	4/4	1.58	Positive	Left	145	AD	AD			
17	70s	Female	3/4	1.52	Positive		97.2	AD				
18	70s	Female	3/4	1.18	Negative		62.8	FTD				
19	70s	Male	3/4	1.40	Positive	Right	134	AD	AD	AD	AD	
20	80s	Male	3/4	1.51	Positive		138	AD	AD			
21	80s	Female	3/3	1.41	Positive	Right	106	CN	CN			
22	70s	Female	3/4	1.48	Positive	Left	55.9	AD	AD			
23	50s	Male	3/3	2.01	Positive		145					

Numbers in bold denote positive biomarker status.

Abbreviations: AD=Alzheimer disease (dementia), CN=cognitively normal, FTD=frontotemporal dementia, UD=uncertain dementia. *Same case as the "Right occipital" case in Table 2.

Conclusions

¹⁸F-flortaucipir PET visual interpretation was found to be consistent between readers in this study.

However, three participants had discordant visual interpretations and SUVRs. In one participant, visual interpretation found elevated uptake in the right precuneus, which was missed by the temporal meta-ROI SUVR. However, when the tau PET images were coregistered with additional T2*-weighted MR imaging, the elevated radiotracer uptake was found to be colocalized with a T2* hypointensity, suggesting a hemorrhagic infarct to be the cause instead of AD tauopathy. All other AD biomarkers were

negative for this participant, supporting this interpretation. Upon review of the additional T2*-weighted MR imaging, the readers also revised their interpretation of the image to be tau negative.

In another participant, visual interpretation found elevated uptake in the occipital lobe, with greater uptake in the left versus right hemisphere, which was also missed by the temporal meta-ROI SUVR. With all other AD biomarkers being positive for this participant, this participant likely has an occipital-predominant form of AD tau pathology [23].

Finally, in the third participant, visual interpretation found elevated uptake in the posterolateral temporal, occipital, and parietal/precuneus regions, with greater uptake in the right versus left hemisphere. The temporal meta-ROI SUVR was borderline negative, suggesting that, perhaps due to the lateralized uptake, the SUVR was artificially low for this case.

Among non-AD sources of ^{18}F -flortaucipir uptake, the most studied is off-target binding in the choroid plexus, striatum, brainstem, and bone/meninges [24,25]. In this study, off-target binding did not mimic the appearance of the AD tau pattern when assessed by visual readers, nor did it cause any tau PET temporal meta-ROI SUVR to be falsely positive when compared to visual interpretation. However, we observed two other sources of off-target binding that were not mentioned in the manufacturer's guidelines for ^{18}F -flortaucipir PET visual interpretation and which can potentially confound tau PET interpretations: hemorrhagic infarcts and meningiomas. The hemorrhagic infarct case was the case previously described as having a tau-positive visual interpretation and a tau-negative SUVR quantification. The two meningioma cases demonstrated elevated levels of radiotracer uptake in the frontal lobe, which is immaterial when assessing tau PET positivity by visual interpretation, but meningiomas in the posterolateral temporal, occipital, or parietal/precuneus regions might plausibly interfere with visual interpretation and SUVR quantification.

When interpreting tau PET visual interpretation alongside clinical diagnosis after the study (both visual interpretation and clinical diagnosis were performed independently) a few relationships between

the two kinds of AD diagnoses were remarkable. First, a baseline tau-positive visual interpretation in participants who were cognitively normal at baseline did not reliably predict conversion to AD dementia at follow up. If anything, tau PET positivity in cognitively normal participants was more likely to be either a sign of atypical AD, of related dementias (vascular dementia or FTD), or of resilience to AD dementia. Second, a baseline tau-negative visual interpretation in participants who were cognitively normal at baseline did not rule out conversion to AD dementia at follow up. Four cases were found to demonstrate conversion to AD dementia at follow up under these circumstances, although two of these were later reassessed to be cognitively normal. Third, baseline tau PET positivity in cognitively impaired participants did not guarantee a diagnosis of AD dementia at follow up: one participant was assessed to be cognitively normal at follow up even under these circumstances and another was reassessed to have FTD. Finally, baseline tau PET negativity in cognitively impaired participants cannot be used to rule out conversion to AD dementia at follow up: three such participants converted to AD dementia at their follow up visits, respectively, although one was reassessed to be cognitively normal at a later date.

A bias of the current study lies in the inclusion of cognitively normal participants. In a clinical setting, ^{18}F -flortaucipir PET is indicated for use in patients with cognitive impairment. Two of the three cases discordant between visual interpretation and SUVR quantification in this study were from cognitively normal participants and would not warrant the use of ^{18}F -flortaucipir visual interpretation in a clinical setting to begin with. Six of the 20 cases discordant between visual interpretation and CSF p-tau181 quantification were from cognitively normal participants and also would not warrant the use of ^{18}F -flortaucipir visual interpretation in a clinical setting. Nonetheless, exploring tau positivity in cognitively normal participants in this study identified individuals who have atypical AD tau and clinical progression.

In conclusion, ^{18}F -flortaucipir PET visual interpretation can identify atypical tauopathy that may be missed by SUVR quantification. However, while the manufacturer's guidelines for ^{18}F -flortaucipir PET

visual interpretation address non-AD sources of uptake such as off-target binding, they do not address other non-AD sources of uptake such as hemorrhagic infarcts and meningiomas. Temporal meta-ROI SUVR was highly concordant with visual interpretation. However, SUVR analyses could not detect lateralized occipital-predominant AD tauopathy. CSF p-tau181 concentration was moderately concordant with visual interpretation and enabled detection of early changes in AD pathophysiology associated with tau hyperphosphorylation. However, these changes cannot be seen on PET. Finally, a positive visual interpretation did not make a follow up diagnosis of AD dementia inevitable, and a negative visual interpretation did not exclude the possibility of a follow up diagnosis of AD dementia. Additional work is needed to understand how multiple AD PET and CSF biomarkers might conceivably be used in tandem in a clinical setting alongside AD clinical evaluation in order to correctly diagnosis and treatment all individuals, not just those who demonstrate AD biomarker and clinical findings concordant with group-level trends.

References

1. Braak H, Alafuzoff I, Arzberger T, Kretschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. *Acta Neuropathol.* 2006;112:389–404.
2. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. *J Neuropathol Exp Neurol.* 2011;70:960–9.
3. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? *Mol Chem Neuropathol.* 1995;26:231–45.
4. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su M-Y, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. *J Alzheimers Dis.* 2013;34:457–68.
5. Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Hodges J, Harada R, et al. In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease. *Eur J Nucl Med Mol Imaging.* 2014;41:816–26.

6. Betthausen TJ, Cody KA, Zammit MD, Murali D, Converse AK, Barnhart TE, et al. In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand 18F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls. *Journal of Nuclear Medicine*. 2019;60:93–9.
7. Jack CR, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut-points for brain aging and Alzheimer’s disease. *Alzheimers Dement*. 2017;13:205–16.
8. Schwarz CG, Therneau TM, Weigand SD, Gunter JL, Lowe VJ, Przybelski SA, et al. Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. *NeuroImage*. 2021;238:118259.
9. Boerwinkle AH, Wisch JK, Chen CD, Gordon BA, Butt OH, Schindler SE, et al. Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease. *Neurology* [Internet]. 2021 [cited 2021 Jun 8]; Available from: <https://n.neurology.org/content/early/2021/04/30/WNL.000000000012123>
10. La Joie R, Bejanin A, Fagan AM, Ayakta N, Baker SL, Bourakova V, et al. Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. *Neurology*. 2018;90:e282–90.
11. Bucci M, Chiotis K, Nordberg A. Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. *Mol Psychiatry*. 2021;1–11.
12. Ossenkoppele R, Reimand J, Smith R, Leuzy A, Strandberg O, Palmqvist S, et al. Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers. *EMBO Mol Med*. 2021;13:e14398.
13. Weintraub S, Salmon D, Mercaldo N, Ferris S, Graff-Radford NR, Chui H, et al. The Alzheimer’s Disease Centers’ Uniform Data Set (UDS): The Neuropsychological Test Battery. *Alzheimer Dis Assoc Disord*. 2009;23:91–101.
14. Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. *Neurology*. 1993;43:2412-2412-a.
15. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. *Journal of Psychiatric Research*. 1975;12:189–98.
16. Su Y, Blazey TM, Snyder AZ, Raichle ME, Marcus DS, Ances BM, et al. Partial volume correction in quantitative amyloid imaging. *NeuroImage*. 2015;107:55–64.
17. Su Y, D’Angelo GM, Vlassenko AG, Zhou G, Snyder AZ, Marcus DS, et al. Quantitative Analysis of PiB-PET with FreeSurfer ROIs. *PLOS ONE*. 2013;8:e73377.
18. Fischl B. FreeSurfer. *NeuroImage*. 2012;62:774–81.
19. Su Y, Flores S, Hornbeck RC, Speidel B, Vlassenko AG, Gordon BA, et al. Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. *NeuroImage Clin*. 2018;19:406–16.

20. Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. *Alzheimers Dement*. 2015;11:1-15.e1-4.
21. Zhu X, Melnykov V. Manly transformation in finite mixture modeling. *Computational Statistics & Data Analysis*. 2018;121:190–208.
22. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2021. Available from: <https://www.R-project.org/>
23. Vogel JW, Young AL, Oxtoby NP, Smith R, Ossenkoppele R, Strandberg OT, et al. Four distinct trajectories of tau deposition identified in Alzheimer’s disease. *Nat Med*. 2021;27:871–81.
24. Baker SL, Harrison TM, Maass A, Joie RL, Jagust WJ. Effect of Off-Target Binding on 18F-Flortaucipir Variability in Healthy Controls Across the Life Span. *Journal of Nuclear Medicine*. 2019;60:1444–51.
25. Smith R, Strandberg O, Leuzy A, Betthausen TJ, Johnson SC, Pereira JB, et al. Sex differences in off-target binding using tau positron emission tomography. *Neuroimage Clin*. 2021;31:102708.

Acknowledgments

We thank the altruism of participants and their families and contributions of Knight ADRC support staff.

Avid Radiopharmaceuticals provided technology transfer and precursor for ¹⁸F-flortaucipir and ¹⁸F-florbetapir. C.D.C. received support from the Knight ADRC T32 Fellowship (5T32AG058518-04) and the NSF GRFP Fellowship (DGE-1745038 and DGE-2139839). S.E.S. received support from NIA R01AG070941 and Barnes-Jewish Hospital Foundation. A.M.F. received support from various NIH grants (P30AG066444, P01AG003991, P01AG026276, U19AG032438). J.C.M. received support from various NIH grants (P30AG066444, P01AG003991, P01AG026276, U19AG032438).

Author contributions

All authors contributed to the study conception and design. Data collection and analysis were performed by Charles D. Chen, Maria Rosana Ponisio, and Jordan A. Lang. The first draft of the manuscript was written by Charles D. Chen and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Disclosure and competing interests statement

C.D.C., J.A.L., and S.F. have no disclosures. M.R.P. received consulting fees from NFL Concussion Settlement Program; and received payment/honoraria from the University of Texas Medical School Galveston (Cooley Visiting Professor for the Department of Radiology). S.E.S. received support from NIA R01AG070941 and Barnes-Jewish Hospital Foundation; received payment/honoraria from the University of Wisconsin, University of Washington, University of Indiana, and St. Luke's Hospital; is a board member of Greater Missouri Alzheimer's Association; and received data on behalf of Washington University from C2N Diagnostics at no cost. A.M.F. received support from various NIH grants (P30AG066444, P01AG003991, P01AG026276, U19AG032438); received consulting fees from DiamiR and Siemens Healthcare Diagnostics Inc.; and participated on an advisory board at Roche Diagnostics, Genentech, and Diadem. J.C.M. received support from various NIH grants (P30AG066444, P01AG003991, P01AG026276, U19AG032438); received consulting fees from Barcelona Brain Research Center and TS Srinivasan Advisory Board; received payment or honoraria from Montefiore Grand Rounds and Tetra-Inst ADRC seminar series; and participated on an advisory board at Cure Alzheimer's Fund. T.L.S.B. has investigator-initiated research funding from NIH, Alzheimer's Association, Barnes-Jewish Hospital foundation, and Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly); participates as a site investigator in clinical trials sponsored by Avid Radiopharmaceuticals, Eli Lilly, Biogen, Eisai, Janssen, and Roche; serves as an unpaid consultant to Eisai and Siemens; and is on the Speaker's Bureau for Biogen.

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.